<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32008155</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients.</ArticleTitle><Pagination><StartPage>2151</StartPage><EndPage>2161</EndPage><MedlinePgn>2151-2161</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-020-04928-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disorder for which Major Histocompatibility Complex (MHC) genes are well-identified as risk factors. SLE patients have different phenotypes or clinical presentations, which vary among Mexicans. This variation could be explained by ethnicity and admixture. Since socioeconomic status probably limits and change the patterns of migration, this factor could favor inbreeding and homogamy in some geographic areas. Consequently, it could alter or restrict the possibilities of admixture too. Therefore, the socioeconomic status may also have implications in the susceptibility and the clinical heterogeneity of SLE in Mexican patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred twenty-three SLE patients and 234 healthy individuals with Mexican admixed ancestry were recruited. HLA alleles were analyzed using the HLA typing method based on Sequence-based typing (SBT).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As expected, it was found an increased frequency of the HLA-DRB1*03:01 allele in all socioeconomic groups when compared with healthy individuals. The susceptibility allele found in the low-income SLE patients was HLA-DRB1*04:05 whereas, the susceptibility alleles for the high-income SLE patients were HLA-DRB1*07:01 (pC&#x2009;=&#x2009;0.03, OR&#x2009;=&#x2009;2.0) and HLA-DRB1*11:04 (pC&#x2009;=&#x2009;0.0004, OR&#x2009;=&#x2009;5.1). Additionally, the frequencies of two protective alleles HLA-DRB1*14:06 (pC&#x2009;=&#x2009;0.01, OR&#x2009;=&#x2009;0.28) and HLA-DRB1*16:02 (pC&#x2009;=&#x2009;0.04, OR&#x2009;=&#x2009;0.22) were found diminished. These findings correlate with the admixture differences between low-income and high-income SLE patients. The clinical manifestations showed a different distribution between both groups. Arthritis and neurological disorder were prevalent in low-income SLE patients, while the hematological disorder was prevalent in high-income SLE patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that HLA class II DRB1 genes contribute to the susceptibility and protection to develop SLE differently depending on socioeconomic status. Due to this, the clinical manifestations vary among patients and it could be related to different admixture charge.Key Point&#x2022; HLA class II DRB1 genes contribute to the susceptibility and protection to develop SLE differently depending on socioeconomic status.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salgado-Galicia</LastName><ForeName>Norma Alicia</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0002-2617-9286</Identifier><AffiliationInfo><Affiliation>Transplant Department, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Do&#xf1;o</LastName><ForeName>Susana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6949-7081</Identifier><AffiliationInfo><Affiliation>Transplant Department, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-G&#xf3;mez</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8110-2214</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3;n Cl&#xed;nica M&#xe9;dica Sur A.C, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakez-Ocampo</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8862-1201</Identifier><AffiliationInfo><Affiliation>Immunology and Rheumatology Department, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfa;&#xf1;iga</LastName><ForeName>Joaqu&#xed;n</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7143-0281</Identifier><AffiliationInfo><Affiliation>Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cos&#xed;o Villegas, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas-Alarc&#xf3;n</LastName><ForeName>Gilberto</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7916-5163</Identifier><AffiliationInfo><Affiliation>Direcci&#xf3;n de Investigaci&#xf3;n, Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acu&#xf1;a</LastName><ForeName>V&#xed;ctor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Escuela Nacional de Antropolog&#xed;a e Historia (ENAH), Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Mar&#xed;a Teresa</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0003-3475-8816</Identifier><AffiliationInfo><Affiliation>Nutrition Institute, Universidad de la Sierra Sur, Miahuatl&#xe1;n de Porfirio D&#xed;az, Oaxaca, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe1;rquez-Garc&#xed;a</LastName><ForeName>Jos&#xe9; Eduardo</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0003-2172-0114</Identifier><AffiliationInfo><Affiliation>Molecular Biology Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cos&#xed;o Villegas, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Lechuga</LastName><ForeName>Maricela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0981-1905</Identifier><AffiliationInfo><Affiliation>Centro M&#xe9;dico Nacional Adolfo Ru&#xed;z Cort&#xed;nez, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorente</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3464-3747</Identifier><AffiliationInfo><Affiliation>Immunology and Rheumatology Department, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Guadalupe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0736-8292</Identifier><AffiliationInfo><Affiliation>Immunology and Rheumatology Department, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineda</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0544-7461</Identifier><AffiliationInfo><Affiliation>Investigador Instituto Nacional de Rehabilitaci&#xf3;n Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Neng</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>HLA Laboratory, The American Red Cross Northeast Division, Dedham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunis</LastName><ForeName>Edmond</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granados</LastName><ForeName>Julio</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8553-1027</Identifier><AffiliationInfo><Affiliation>Transplant Department, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, Mexico. julgrate@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>000 000 000273175</GrantID><Agency>Consejo Nacional de Ciencia y Tecnolog&#xed;a de M&#xe9;xico (CONACYT)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007182" MajorTopicYN="Y">Income</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012923" MajorTopicYN="Y">Social Class</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA-DRB1 alleles</Keyword><Keyword MajorTopicYN="N">High-income</Keyword><Keyword MajorTopicYN="N">Low-income</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32008155</ArticleId><ArticleId IdType="doi">10.1007/s10067-020-04928-5</ArticleId><ArticleId IdType="pii">10.1007/s10067-020-04928-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghodke-Puranik Y, Niewold TB (2015) Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun 64:125&#x2013;136. https://doi.org/10.1016/j.jaut.2015.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.08.004</ArticleId><ArticleId IdType="pubmed">26324017</ArticleId><ArticleId IdType="pmc">4628859</ArticleId></ArticleIdList></Reference><Reference><Citation>Valencia-Flores M, Res&#xe9;ndiz MC, Santiago V, Casta&#xf1;o V, Granados J, Camarena A et al (2010) Sleep, fatigue, depression, and pain in Mexican women with systemic lupus erythematosus: an exploratory study. Hisp Heal Care Int 8(4):217&#x2013;226. https://doi.org/10.1891/1540-4153.8.4.217</Citation><ArticleIdList><ArticleId IdType="doi">10.1891/1540-4153.8.4.217</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12(10):605&#x2013;620. https://doi.org/10.1038/nrrheum.2016.137</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId><ArticleId IdType="pubmed">27558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Reis PC, Sullivan KE (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12(12):716&#x2013;730. https://doi.org/10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Walid W, Noor Eldeen E, Essam HM, Adel A, Khaled DH, Hamad AA et al (2014) Relation between HLA typing and clinical presentations in systemic lupus erythematosus patients in Al-Qassim region, Saudi Arabia. Int J Health Sci (Qassim) 8(2):159&#x2013;165</Citation><ArticleIdList><ArticleId IdType="doi">10.12816/0006082</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasconcelos C, Carvalho C, Pereira C, Bettencourt A, Costa PP, Barbosa P et al (2009) HLA in Portuguese systemic lupus erythematosus patients and their relation to clinical features. Ann N Y Acad Sci 580:575&#x2013;580. https://doi.org/10.1111/j.1749-6632.2009.04873.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04873.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Granados J, Z&#xfa;&#xf1;iga J, Acu&#xf1;a-Alonzo V, Rosetti F, Vargas-Alarc&#xf3;n G (2006) Influencia de alelos y haplotipos del complejo principal de histocompatibilidad en la susceptibilidad a lupus eritematoso generalizado en la poblaci&#xf3;n mexicana. Gac Med Mex 142(3):195&#x2013;199</Citation><ArticleIdList><ArticleId IdType="pubmed">16875346</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa H, Kawasaki A, Oka S, Ito I, Shimada K, Sugii S, Hashimoto A, Komiya A, Fukui N, Kondo Y, Ito S, Hayashi T, Matsumoto I, Kusaoi M, Amano H, Nagai T, Hirohata S, Setoguchi K, Kono H, Okamoto A, Chiba N, Suematsu E, Katayama M, Migita K, Suda A, Ohno S, Hashimoto H, Takasaki Y, Sumida T, Nagaoka S, Tsuchiya N, Tohma S (2014) Human leukocyte antigens and systemic lupus erythematosus: a protective role for the HLA-DR6 alleles DRB1*13:02 and *14:03. PLoS One 9(2):1&#x2013;7. https://doi.org/10.1371/journal.pone.0087792</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Bang SY, Lee HS, Okada Y, Han B, Saw WY, Teo YY, Bae SC (2014) The HLA-DR&#x3b2;1 amino acid positions 11-13-26 explain the majority of SLE-MHC associations. Nat Commun 5:5902. https://doi.org/10.1038/ncomms6902</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6902</ArticleId><ArticleId IdType="pubmed">25533202</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli F, Perricone C, Borgiani P, Ciccacci C, Rufini S, Cipriano E et al (2015) Genetic factors in systemic lupus erythematosus: contribution to disease phenotype. J Immunol Res 2015:1&#x2013;11. https://doi.org/10.1155/2015/745647</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/745647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, Abadi I, Caeiro F, Alvarellos A, Alarc&#xf3;n-Segovia D, Grupo Latinoamericano de Estudio del Lupus (2004) The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among &#x201c;Hispanics&#x201d;. Medicine. 83(1):1&#x2013;17. https://doi.org/10.1097/01.md.0000104742.42401.e2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000104742.42401.e2</ArticleId><ArticleId IdType="pubmed">14747764</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Estrada A, Gignoux CR, Fernandez-Lopez JC, Zakharia F, Sikora M, Contreras AV et al (2014) The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science 344(6189):1280&#x2013;1285. https://doi.org/10.1126/science.1251688</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1251688</ArticleId><ArticleId IdType="pubmed">24926019</ArticleId><ArticleId IdType="pmc">4156478</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno F, Gojobori J, Wang L, Onishi K, Sugiyama S, Granados J, Gomez-Trejo C, Acu&#xf1;a-Alonzo V, Ueda S (2014) Complete mitogenome analysis of indigenous populations in Mexico: its relevance for the origin of Mesoamericans. J Hum Genet 59(7):359&#x2013;367. https://doi.org/10.1038/jhg.2014.35</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jhg.2014.35</ArticleId><ArticleId IdType="pubmed">24804703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725&#x2013;1734. https://doi.org/10.1002/1529-0131(199709)40:9&lt;1725::AID-ART29&gt;3.0.CO;2-Y</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199709)40:9&lt;1725::AID-ART29&gt;3.0.CO;2-Y</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarc&#xf3;n-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19(10):1551&#x2013;1558</Citation><ArticleIdList><ArticleId IdType="pubmed">1464867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630&#x2013;640</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfa;&#xf1;iga J, Yu N, Barquera R, Alosco S, Ohashi M, Lebedeva T, Acu&#xf1;a-Alonzo V, Yunis M, Granados-Montiel J, Cruz-Lagunas A, Vargas-Alarc&#xf3;n G, Rodr&#xed;guez-Reyna TS, Fernandez-Vi&#xf1;a M, Granados J, Yunis EJ (2013) HLA class I and class II conserved extended haplotypes and their fragments or blocks in Mexicans: implications for the study of genetic diversity in admixed populations. PLoS One 8(9). https://doi.org/10.1371/journal.pone.0074442</Citation></Reference><Reference><Citation>Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE (2001) IMGT/HLA database-a sequence database for the human major histocompatibility complex. Nucleic Acids Res 29(1):210&#x2013;213</Citation></Reference><Reference><Citation>Lebedeva TV, Mastromarino SA, Lee E, Ohashi M, Alosco SM, Yu N (2011) Resolution of HLA class I sequence-based typing ambiguities by group-specific sequencing primers. Tissue Antigens 77(3):247&#x2013;250. https://doi.org/10.1111/j.1399-0039.2010.01616.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.2010.01616.x</ArticleId><ArticleId IdType="pubmed">21299532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J (2003) Maximum-likelihood estimation of admixture proportions from genetic data. Genetics. 164:747&#x2013;765</Citation><ArticleIdList><ArticleId IdType="pubmed">12807794</ArticleId><ArticleId IdType="pmc">1462571</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-sanchez J (2002) Molecular analysis of HLA-DRB1 polymorphism in north-east Spain. Eur J Immunogenet 29:75&#x2013;77. https://doi.org/10.1046/j.0960-7420.2001.00293.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0960-7420.2001.00293.x</ArticleId><ArticleId IdType="pubmed">11841495</ArticleId></ArticleIdList></Reference><Reference><Citation>Paximadis M, Mathebula TY, Gentle NL, Vardas E, Colvin M, Gray CM, Tiemessen CT, Puren A (2012) Human leukocyte antigen class I (A,B,C) and II (DRB1) diversity in the black and Caucasian South African population. Hum Immunol 73(1):80&#x2013;92. https://doi.org/10.1016/j.humimm.2011.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2011.10.013</ArticleId><ArticleId IdType="pubmed">22074999</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaiz-villena A, Vargas-alarco G, Areces C, Enr&#x131; M, Abd-el-fatah-khalil S, Ferna M et al (2014) Mixtec Mexican Amerindians : an HLA alleles study for America peopling, pharmacogenomics, and transplantation. Immunol Investig 43(8):738&#x2013;755. https://doi.org/10.3109/08820139.2014.926369</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08820139.2014.926369</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Ort&#xed;z J, Sandoval-Ram&#xed;rez L, Rangel-Villalobos H, Maldonado-Torres H, Cox S, Garc&#xed;a-Sep&#xfa;lveda C et al (2006) High-resolution molecular characterization of the HLA class I and class II in the Tarahumara Amerindian population. Tissue Antigens 68(5):135&#x2013;146. https://doi.org/10.1111/j.1399-0039.2006.00636.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.2006.00636.x</ArticleId><ArticleId IdType="pubmed">16866883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda N, Kojima H, Nishikawa M, Hayashi K, Futagami T, Tsujino T, Kusunoki Y, Fujii N, Suegami S, Miyazaki Y, Middleton D, Tanaka H, Saji H (2015) Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens 85:252&#x2013;259. https://doi.org/10.1111/tan.12536</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.12536</ArticleId><ArticleId IdType="pubmed">25789826</ArticleId><ArticleId IdType="pmc">5054903</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Arcelus M, Rich SS, Raychaudhuri S (2016) Autoimmune diseases connecting risk alleles with molecular traits of the immune system. Nat Rev Genet 17(3):160&#x2013;174. https://doi.org/10.1038/nrg.2015.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2015.33</ArticleId><ArticleId IdType="pubmed">26907721</ArticleId><ArticleId IdType="pmc">4896831</ArticleId></ArticleIdList></Reference><Reference><Citation>Repeinertsen JL, Klippel JH, Jonhson AH, Steinberg AD, Decker JL, Mann DL (1978) B-lymphocyte alloantigens associated with systemic lupus erythematous. N Engl J Med 299(10). https://doi.org/10.1056/NEJM197809072991004</Citation></Reference><Reference><Citation>Vargas-Alarc&#xf3;n G, Salgado N, Granados J, G&#xf3;mez-Casado E, Martinez-Laso J, Alcocer-Varela J, Arnaiz-Villena A, Alarc&#xf3;n-Segovia D (2001) Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: the relevance of considering homologous chromosomes in determining susceptibility. Hum Immunol 62(8):814&#x2013;820. https://doi.org/10.1016/j.humimm.2004.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2004.09.008</ArticleId><ArticleId IdType="pubmed">11476905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekker-Mendez C, Yamamoto-Furusho JK, Vargas-Alarcon G, Ize-Ludlow D, Alcocer-Varela J, Granados J (1998) Haplotype distribution of class II MHC genes in Mexican patients with systemic lupus erythematosus. Scand J Rheumatol 27(5):373&#x2013;376</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009749850154410</ArticleId></ArticleIdList></Reference><Reference><Citation>Granados J, Vargas-Alarc&#xf3;n G, Andrade F, Melin-Aldana et al (1996) The role of HLA-DR alleles and complotypes through the ethnic barrier in systemic lupus erythematosus in Mexicans. Lupus. 5:184&#x2013;189. https://doi.org/10.1177/096120339600500304</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339600500304</ArticleId><ArticleId IdType="pubmed">8803888</ArticleId></ArticleIdList></Reference><Reference><Citation>Penaranda-Parada E, Quintana G, Yunis JJ, Mantilla R, Rojas W, Panqueva U et al (2015) Clinical, serologic, and immunogenetic characterization (HLA-DRB1) of late-onset lupus erythematosus in a Colombian population. Lupus. 24(12):1293&#x2013;1299. https://doi.org/10.1177/0961203315588576</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315588576</ArticleId><ArticleId IdType="pubmed">26022697</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E, Williams A, Beck S, Kyogoku C, Moser K, Gaffney P, Gregersen PK, Criswell LA, Harley JB, Behrens TW (2007) Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet 15:823&#x2013;830</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejhg.5201827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto H, Nishimura Y, Dong RP, Kimura A, Sasazuki T, Vamanakal K et al (1994) HLA antigens in Japanese patients with systemic lupus erythematosus. Rheumatology. 23(4):191&#x2013;196</Citation></Reference><Reference><Citation>Suggs MJL, Majithia V, Lewis RE, Cruse JM (2011) HLA DRB1*15:03 allelic haplotype predominance and associated immunodysregulation in systemic lupus erythematosus. Exp Mol Pathol. 91:548&#x2013;562. https://doi.org/10.1016/j.yexmp.2011.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2011.03.006</ArticleId><ArticleId IdType="pubmed">21497601</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu Z, Zhang P, Tong Y (2015) Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis 18(1):17&#x2013;28. https://doi.org/10.1111/1756-185X.12528</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12528</ArticleId><ArticleId IdType="pubmed">25546242</ArticleId></ArticleIdList></Reference><Reference><Citation>Granados J, Vargas-Alarc&#xf3;n G, Drenkard C, Andrade F, Mel&#xed;n-Aldana H, Alcocer-Varela J, Alarc&#xf3;n-Segovia D (1997) Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE). Lupus. 6(1):57&#x2013;62 http://www.ncbi.nlm.nih.gov/pubmed/9116720</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339700600108</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabace S, Nicotra M, Cappellacci S, Morellini M, Muttinelli C, Anna M et al (1991) HLA-DR and DQ antigens and anticardiolipin antibodies in women with recurrent spontaneous abortions. Am J Reprod Immunol 26:147&#x2013;149</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0897.1991.tb00715.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzer S, Pabinger I, Gschwandtner ME, Mayr WR, Hutter D (1997) Lupus anticoagulants : strong association with the major histocompatibility complex class II and platelet antibodies. Br J Haematol 98:342&#x2013;345</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.1997.2103027.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Camps MT, Cuadrado MJ, Oc&#xf3;n P, et al (1995) Association between HLA class II antigens and primary antiphospholipid syndrome from the south of Spain. Lupus 4(1):51&#x2013;55. https://doi.org/10.1177/096120339500400111</Citation></Reference><Reference><Citation>Gonz&#xe1;lez-Galarza FF, Takeshita LYC, Santos EJM, Kempson F, Thomaz Maia MH, Soares da Silva AL, Teles e Silva AL, Ghattaoraya GS, Alfirevic A, Jones A and Derek M (2015). Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Research. 43: 784&#x2013;788, https://doi.org/10.1093/nar/gku1166 . Allele Frequencies in Worldwide populations [Internet]. [Revised on April 2019] http://allelefrequencies.net/hla6006a.asp?hla_locus_type=Classical&amp;hla_locus=DRB1&amp;hla</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>